{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:03:26Z","timestamp":1783001006863,"version":"3.54.5"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jtos.2020.05.003","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T13:10:40Z","timestamp":1589980240000},"page":"128-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["The effects of systemic cyclosporine in acute Stevens-Johnson syndrome\/toxic epidermal necrolysis on ocular disease"],"prefix":"10.1016","volume":"19","author":[{"given":"Leangelo N.","family":"Hall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapna S.","family":"Shanbhag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy","family":"Rashad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Chodosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajirah N.","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtos.2020.05.003_bib1","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/00007611-198005000-00015","article-title":"Etiologic factors of the Stevens- johnson syndrome","volume":"73","author":"Yetiv","year":"1980","journal-title":"South Med J"},{"key":"10.1016\/j.jtos.2020.05.003_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2500\/108854195778666847","article-title":"Virus induced erythema multi- forme and Stevens-Johnson syndrome","volume":"16","author":"Choy","year":"1995","journal-title":"Allergy Proc"},{"key":"10.1016\/j.jtos.2020.05.003_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/adc.53.1.38","article-title":"Mycoplasma pneumoniae in- fections in children","volume":"53","author":"Stevens","year":"1978","journal-title":"Arch Dis Child"},{"issue":"11","key":"10.1016\/j.jtos.2020.05.003_bib4","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/S0161-6420(95)30811-1","article-title":"Analysis of the acute ophthalmic manifestations of the erythema multiforme\/Stevens-Johnson syndrome\/toxic epidermal necrolysis disease spectrum","volume":"102","author":"Power","year":"1995","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.jtos.2020.05.003_bib5","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/ICU.0000000000000312","article-title":"Ocular manifestations of Stevens\u2013Johnson syndrome and their management","volume":"27","author":"Saeed","year":"2016","journal-title":"Curr Opin Ophthalmol"},{"issue":"1","key":"10.1016\/j.jtos.2020.05.003_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.BCR.0000150215.78220.79","article-title":"Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center","volume":"26","author":"Haber","year":"2005","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.jtos.2020.05.003_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000070938","article-title":"Dermatological and ophthalmological sequels in toxic epidermal necrolysis","volume":"207","author":"Magina","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.jtos.2020.05.003_bib8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jaad.2013.05.002","article-title":"Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment","volume":"69","author":"Schwartz","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jtos.2020.05.003_bib9","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jtos.2016.02.001","article-title":"Acute and chronic ophthalmic & involvement in Stevens \u2013 johnson syndrome\/toxic epidermal necrolysis \u2013 a comprehensive review and guide to therapy. II. Ophthalmic disease","volume":"14","author":"Kohanim","year":"2016","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2020.05.003_bib10","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/archopht.1973.01000050378008","article-title":"Ocular aftermath of Stevens-Johnson syndrome","volume":"90","author":"Arstikaitis","year":"1973","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.jtos.2020.05.003_bib11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ophtha.2014.08.013","article-title":"The role of systemic immunomodulatory treatment and prognostic factors on chronic ocular complications in Stevens\u2013Johnson syndrome","volume":"122","author":"Kim","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2020.05.003_bib12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1529-8019.2011.01396.x","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a review of treatment options","volume":"24","author":"Worswick","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jtos.2020.05.003_bib13","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/pde.12029","article-title":"Toxic epidermal necrolysis in a child successfully treated with infliximab","volume":"31","author":"Scott-Lang","year":"2014","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jtos.2020.05.003_bib14","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomised comparison of thalidomide versus placebo in toxic epider- mal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jtos.2020.05.003_bib15","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/sj.eye.6701653","article-title":"High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits","volume":"19","author":"Yip","year":"2004","journal-title":"Eye"},{"key":"10.1016\/j.jtos.2020.05.003_bib16","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jaad.2014.07.016","article-title":"Retrospective review of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with CsA","volume":"71","author":"Kirchhof","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jtos.2020.05.003_bib17","first-page":"24","article-title":"Cyclosporine for SJS\/TEN: a case series and review of the literature","volume":"87","author":"Reese","year":"2011","journal-title":"Cutis"},{"key":"10.1016\/j.jtos.2020.05.003_bib18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2133.2005.06721.x","article-title":"Toxic epidermal necroly- sis: current evidence, practical management and future directions","volume":"153","author":"Chave","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jtos.2020.05.003_bib19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005373-200003000-00017","article-title":"Treatment of toxic epidermal necrolysis with cyclosporin A","volume":"48","author":"Ar\u00e9valo","year":"2000","journal-title":"J Trauma"},{"key":"10.1016\/j.jtos.2020.05.003_bib20","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","article-title":"Open trial of ciclosporin treatment for Stevens\u2013Johnson syn- drome and toxic epidermal necrolysis","volume":"163","author":"Valeyrie-Allanore","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jtos.2020.05.003_bib21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/JIR.S160964","article-title":"A meta-analysis of cyclosporine treatment for Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"11","author":"Ng","year":"2018","journal-title":"J Inflamm Res"},{"issue":"6","key":"10.1016\/j.jtos.2020.05.003_bib22","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"7","key":"10.1016\/j.jtos.2020.05.003_bib23","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.ophtha.2006.10.029","article-title":"New grading system for the evaluation of chronic ocular manifestations in patients with Stevens\u2013Johnson syndrome","volume":"114","author":"Sotozono","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2020.05.003_bib24","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1089\/jop.2012.0009","article-title":"Efficacy of cyclosporine 0.05% eye drops in Stevens Johnson syndrome with chronic dry eye","volume":"29","author":"Prabhasawat","year":"2013","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2020.05.003_bib25","first-page":"312","article-title":"Effectiveness, safety and tolerability of cyclosporine versus supportive treatment in Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis: a record-based study","volume":"3","author":"Mohanty","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012420300811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012420300811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:39:21Z","timestamp":1761539961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012420300811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":25,"alternative-id":["S1542012420300811"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2020.05.003","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of systemic cyclosporine in acute Stevens-Johnson syndrome\/toxic epidermal necrolysis on ocular disease","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2020.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}